Gupta Vikas, Dwivedi Gunjan, Chugh Rajeev, Sahu Pankaj Kumar, Gupta Devendra Kumar, Basu Abhijit, Upadhyay Kiran, Patnaik Uma, Bhatia Ritika
Department of ORL-HNS, Command Hospital, Lucknow, Uttar Pradesh India.
Department of ORL-HNS, Command Hospital, Pune, Maharashtra India.
Indian J Otolaryngol Head Neck Surg. 2022 Dec;74(Suppl 3):6078-6086. doi: 10.1007/s12070-021-02746-y. Epub 2021 Jul 9.
Chyle leak is a dreadful complication in patients undergoing neck dissections. Octreotide has been used in the management of chyle leak post neck dissections in head and neck cancer patients. Currently there is no consensus and practice guidelines on the same. (1) To study the role of octreotide in early cessation of post neck dissection chyle leak. (2) To study incidence of intra-operative and post-operative CL, its relation to the extent of nodal disease and neck dissection, prior radiotherapy. Retrospective analysis of 16 patients out of 529 neck dissection over a period of 03 years between Jan 2016 and Dec 2019 who developed post-operative chyle leak. All patients who had post-operative chyle leak were administered octreotide. Time taken for chyle leak to stop was primary outcome. Secondary outcomes were duration of hospitalization post-operatively, incidence of intra-operative and post-operative chyle leak, its relation to the extent of nodal disease, prior radiotherapy and type of neck dissection. 59 of 529 neck dissections (11.15%) were noted to have intra-operative chyle leak. 16 of 529 neck dissections (3.02%) developed post-operative chyle leak. On applying chi square test, prior multimodality and N plus neck were found to be significant risk factors in developing postoperative chyle leak. Considering only RT versus no RT in prior multimodality treated group, the difference was insignificant. Onset of chyle leak varied from 1 to 5 post-op day (mean 2.68 days). 15 (93.75%) patients responded to octreotide. Chyle leak resolved between 3 and 10 days (mean 5.18 days) and octreotide was given for 5-12 days (mean-7.18 days). Overall duration of hospitalization ranged from 09 to 18 days (mean 12.18 days). 01 patient (6.25%) had to be re-explored due to high volume leak despite using octreotide. Adverse effects of octreotide were minimal and tolerable. Octreotide is effective in reducing the duration of chyle leak, hospital stay and need for surgical intervention. It may be considered as suitable adjunct to conservative measures in the management for post-operative chyle leak.
乳糜漏是接受颈部清扫术患者的一种可怕并发症。奥曲肽已被用于头颈部癌患者颈部清扫术后乳糜漏的管理。目前对此尚无共识和实践指南。(1)研究奥曲肽在早期终止颈部清扫术后乳糜漏中的作用。(2)研究术中及术后乳糜漏的发生率、其与淋巴结疾病范围和颈部清扫的关系、既往放疗情况。对2016年1月至2019年12月3年间529例颈部清扫术中16例发生术后乳糜漏的患者进行回顾性分析。所有术后发生乳糜漏的患者均给予奥曲肽治疗。乳糜漏停止所需时间为主要结局。次要结局包括术后住院时间、术中及术后乳糜漏的发生率、其与淋巴结疾病范围、既往放疗及颈部清扫类型的关系。529例颈部清扫术中59例(11.15%)有术中乳糜漏。529例颈部清扫术中16例(3.02%)发生术后乳糜漏。应用卡方检验发现,既往多模式治疗和N加颈部是发生术后乳糜漏的显著危险因素。在既往多模式治疗组中仅考虑放疗与未放疗,差异无统计学意义。乳糜漏的发生时间为术后1至5天(平均2.68天)。15例(93.75%)患者对奥曲肽有反应。乳糜漏在3至10天内消失(平均5.18天),奥曲肽给药5至12天(平均7.18天)。总体住院时间为9至18天(平均12.18天)。1例患者(6.25%)尽管使用了奥曲肽,但因乳糜漏量过大仍需再次手术探查。奥曲肽的不良反应轻微且可耐受。奥曲肽可有效缩短乳糜漏持续时间、住院时间及减少手术干预需求。在术后乳糜漏的管理中,它可被视为保守治疗措施的合适辅助手段。